New study tests safer bleeding control for hemophilia a patients on emicizumab

NCT ID NCT04563520

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study is testing whether a low, personalized dose of FEIBA (aPCC) can safely control bleeding in children and adults with hemophilia A who have inhibitors and are already taking emicizumab. The study will measure how well the blood clots after FEIBA is given and track any serious side effects. Only 5 participants are being enrolled, so results will be very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Emicizumab (Hemlibra) and FEIBA (activated prothrombin complex concentrate)
What this could lead to: If successful, this could show that a low, personalized dose of FEIBA is safe and effective for managing breakthrough bleeding in people with hemophilia A and inhibitors who are already on emicizumab.
What could go wrong: This is a very small study (only 5 participants) and is still recruiting. It focuses on lab measures of clotting, not long-term outcomes, so results may not apply broadly. There is also a risk of blood clots or other serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

Children's Healthcare of Atlanta
RECRUITING

Atlanta, Georgia, 30322, United States
Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.